As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with ...

安尼可®, approved for marketing in August 2021, is currently the only differentiated PD-1 monoclonal antibody that applies the IgG1 subtype with modified Fc-null domain. 开坦尼® (PD-1/CTLA ...